Vapotherm Director James Liken Sells $15,956 in Stock and Disposes of Additional $119,481 Worth

In a recent development, James W. Liken, a director at Vapotherm Inc, a company focused on surgical and medical instruments, liquidated a portion of his shares in the company. On January 22, 2024, Liken sold 17,500 shares at a weighted average price of $0.9118 each, totaling around $15,956.

Further, on September 20, 2024, Liken disposed of 50,308 shares at a price of $2.18 per share, followed by the sale of an additional 4,500 shares at the same price. These transactions, associated with a merger agreement, accumulated to a total of $119,481.

These sales were reported in a regulatory filing with the Securities and Exchange Commission. It appears that after these transactions, Liken holds no shares of Vapotherm’s common stock. The reported sale prices for the shares varied between $0.88 and $0.92, while the disposals were executed at a fixed price of $2.18.

Details about the number of shares sold at each price can be requested, as outlined in the footnotes of the SEC filing. These footnotes clarify that the disposals were part of a merger agreement that included a cash payment per share.

Insider stock transactions at Vapotherm are closely monitored by investors, providing valuable insights into the company’s performance and the perspectives of insiders on the stock’s value.

### Investing Insights

For those observing Vapotherm Inc, it’s essential to consider the company’s financial standing and market behavior. Vapotherm, recognized for its medical and surgical instruments, has a market capitalization of approximately $13.59 million, categorizing it as a small-cap stock, which may involve higher volatility and distinct market risks.

Recent data showcases that Vapotherm’s stock has surged by 64.08% over the last six months, reflecting a notable increase in its value. This price movement aligns with indications that the stock has seen significant appreciation over a similar period, particularly leading up to the insider transactions by James W. Liken.

Additionally, it’s important to note that Vapotherm is burdened with considerable debt and has been rapidly consuming cash. These factors are critical for investors to evaluate in light of the recent insider sales, as they may relate to the company’s financial strategy and potential liquidity issues. Vapotherm’s short-term liabilities currently exceed its liquid assets, raising concerns about possible liquidity challenges in the near future.

For those seeking deeper insights, additional analysis about Vapotherm’s financial standing and stock performance is available through various resources, including metrics and evaluations specific to the company.

While Liken’s recent sales have attracted attention, these insights can assist investors in forming a well-rounded view of Vapotherm’s current financial health and future outlook.